A5067018616- Renal cell carcinoma treatment
- Bladder and Urothelial Cancer Treatments
- Multiple and Secondary Primary Cancers
- Renal and related cancers
- Urinary and Genital Oncology Studies
- Cancer Immunotherapy and Biomarkers
- Urinary Tract Infections Management
- Cancer Genomics and Diagnostics
- Ferroptosis and cancer prognosis
- Polyomavirus and related diseases
- Organ Donation and Transplantation
- Prostate Cancer Treatment and Research
- Cytomegalovirus and herpesvirus research
- Cancer-related gene regulation
- Viral-associated cancers and disorders
- Epigenetics and DNA Methylation
- Urological Disorders and Treatments
Chiba University
2022-2024
Some researchers have found that preoperative pyuria is a risk factor for recurrence after transurethral resection of high-risk non-muscle invasive bladder cancer. However, to our knowledge, none clarified the risks associated with according bacille Calmette-Guerin (BCG) treatment status. We retrospectively selected patients cancer Japanese Urological Association guidelines. Pyuria was defined as ≥10 white blood cells per high-powered field. analyzed recurrence-free rates (RFS) in 424 who...
The authors declare no conflict of interest.
Combination therapy of nivolumab and ipilimumab (NIVO + IPI) for metastatic renal cell carcinoma (mRCC) has shown efficacy, but approximately 20% patients experience disease progression in the early stages treatment. No useful biomarkers have been reported to date. Therefore, it is desirable identify predict treatment responses advance. We examined tumor microenvironment (TME)-related gene expression mRCC treated with NIVO IPI, between response non-response groups, using tissues, before...
Abstract Objectives Renal cell carcinoma (RCC) is shown to have a tendency for late recurrence, occurring 5 or more years after curative surgery. Imaging diagnosis required follow‐up, and there no definitive answer as how long this should continue. Some patients discontinue follow‐up visits at their own discretion. How best predict recurrence loss (LF) remains unclear. Patients methods This study targeted diagnosed with non‐metastatic RCC who underwent either radical partial nephrectomy...
Combination therapy using immuno-oncology drugs with tyrosine kinase inhibitors is increasingly important in the therapeutic strategy for metastatic renal cell carcinomas. Here, we report a case of carcinoma that was successfully treated deferred cytoreductive nephrectomy following lenvatinib plus pembrolizumab combination therapy.A 49-year-old man referred to our hospital diagnosis advanced right kidney cancer multiple lung metastases (cT3aN0M1). The size primary tumor so huge it exceeded...
Few reports have presented sporadic multifocal renal cell carcinomas of different histologic types occurring simultaneously in a single kidney. Here, we present case three ipsilateral with types.A 44-year-old man end-stage disease due to nephrosclerosis was referred our hospital for an incidental tumor. Following the introduction hemodialysis, enhanced computed tomography revealed tumor suggestive clear-cell carcinoma cystic component. With preoperative diagnosis one tumor, he underwent...
Figure S1. Photodynamic diagnosis findings in the second transurethral resection. Table Patient characteristics. S2. details. Please note: The publisher is not responsible for content or functionality of any supporting information supplied by authors. Any queries (other than missing content) should be directed to corresponding author article.
The incidence of bladder cancer following transplantation is high; however, no previous studies have reported the development bone marrow and bilateral lung transplantations.A 42-year-old man who was followed for due to chronic graft-versus-host disease complained gross hematuria. Transurethral resection tumor performed cT1N0M0 cancer. On night, he experienced severe respiratory failure intubated. He discharged on postoperative day 32 with introduction home oxygen therapy. pathological...